dc.date.accessioned | 2021-08-09T16:01:40Z | |
dc.date.available | 2021-08-09T16:01:40Z | |
dc.date.created | 2021-07-21T13:46:05Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Fossmark, Reidar Olaisen, Maya Martinsen, Tom Christian Melberg, Hans Olav . Factors associated with the persistence of oral 5-aminosalicylic acid monotherapy in ulcerative colitis: a nationwide Norwegian cohort study. Therapeutic Advances in Gastroenterology. 2021, 14, 1-10 | |
dc.identifier.uri | http://hdl.handle.net/10852/86727 | |
dc.description.abstract | Background: Oral 5-aminosalicylic acid (5-ASA) is the mainstay treatment of ulcerative colitis (UC) and therapy with oral 5-ASA is associated with beneficial outcomes. We have examined factors associated with the persistence of oral 5-ASA treatment in a national cohort of UC patients. Methods: Patients with newly diagnosed UC from 2010 to 2014 using oral 5-ASA monotherapy were identified by combining data from the Norwegian Patient Registry and the Norwegian Prescription Database. The median follow-up time was 1029 days. Drug persistence was defined as duration of oral 5-ASA preparation as monotherapy. Non-persistence of a oral 5-ASA preparation as monotherapy was defined as stopping oral 5-ASA, initiation of any further anti-inflammatory treatment including a course of glucocorticoids and a change to another oral 5-ASA preparation. Drug persistence was analyzed using the Kaplan–Meier method and influence of covariates on drug persistence was analyzed with the Cox proportional hazard model. Results: A total of 3421 patients were identified. The overall median 5-ASA drug persistence was 179 days. In univariate analyses, persistence was associated with preparation type and high-dose treatment, while oral glucocorticoid use or hospitalization around the start of oral 5-ASA were associated with shorter 5-ASA persistence. In multivariate analyses, oral glucocorticoids [HR 1.67 (1.54–1.80), p < 0.005] and hospitalization around start of 5-ASA [HR 1.23 (1.14–1.34), p < 0.005] were associated with non-persistence, whereas high dose (⩾3 g/day) 5-ASA was associated with longer persistence [HR 0.68 (0.65–0.71), p < 0.005]. Conclusion: High-dose treatment with oral 5-ASA was associated with longer persistence of oral 5-ASA monotherapy, whereas the presence of factors indicating more severe disease around initiation of 5-ASA monotherapy was associated with a shorter persistence. | |
dc.language | EN | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0/ | |
dc.title | Factors associated with the persistence of oral 5-aminosalicylic acid monotherapy in ulcerative colitis: a nationwide Norwegian cohort study | |
dc.type | Journal article | |
dc.creator.author | Fossmark, Reidar | |
dc.creator.author | Olaisen, Maya | |
dc.creator.author | Martinsen, Tom Christian | |
dc.creator.author | Melberg, Hans Olav | |
cristin.unitcode | 185,52,0,0 | |
cristin.unitname | Institutt for helse og samfunn | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.cristin | 1922345 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Therapeutic Advances in Gastroenterology&rft.volume=14&rft.spage=1&rft.date=2021 | |
dc.identifier.jtitle | Therapeutic Advances in Gastroenterology | |
dc.identifier.volume | 14 | |
dc.identifier.doi | https://doi.org/10.1177/17562848211021760 | |
dc.identifier.urn | URN:NBN:no-89370 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 1756-283X | |
dc.identifier.fulltext | Fulltext https://www.duo.uio.no/bitstream/handle/10852/86727/1/Fossmark%2B2021%2B17562848211021760.pdf | |
dc.type.version | PublishedVersion | |
cristin.articleid | 175628482110217 | |